对比DEB-TACE与cTACE治疗不可切除的肝内胆管细胞癌的有效性及安全性

肝脏 ›› 2022, Vol. 27 ›› Issue (12): 1292-1295.

对比DEB-TACE与cTACE治疗不可切除的肝内胆管细胞癌的有效性及安全性

何海涛, 刘尚大, 韦广旭, 许康祥, 周鹏程

223001 江苏淮安东部战区总医院淮安医疗区影像科(何海涛);淮安第八二医院影像科(刘尚大,许康祥,周鹏程);海军军医大学第一附属医院介入治疗科(韦广旭)

收稿日期:2022-02-08 发布日期:2023-01-30
通讯作者: 何海涛,Email:pla82hht@126.com

The efficacy and safety of DEB-TACE compared with cTACE in the treatment of unresectable intrahepatic cholangiocarcinoma

HE Hai-tao¹, LIU Shang-da², WEI Guang-xu³, XU Kang-xiang², ZHOU Peng-cheng²

1. Department of Radiology, Huai-an Medical District of Eastern Theater General Hospital, Jiangsu 223001, China;
2. Department of Radiology, Huai’an No.82 Hospital, Jiangsu 223001, China;
3. Department of Intervention, First Affiliated Hospital of Navy Military Medical University, Shanghai 200433, China

Received:2022-02-08 Published:2023-01-30
Contact: HE Hai-tao,Email:pla82hht@126.com

摘要/Abstract

摘要： 目的比较载药微球的经动脉化疗栓塞术(DEB-TACE)与传统的经动脉化疗栓塞术(cTACE)治疗不可切除的肝内胆管细胞癌(ICC)的有效性及安全性。方法选择2016年5月1日至2021年5月1日海军军医大学第一附属医院收治的ICC患者35例,其中17例接受DEB-TACE治疗,18例接受cTACE治疗。术后4~8周根据实体瘤疗效评估标准(RECIST)进行评估,并随访患者的生存情况。记录术后两组患者的不良事件并进行对比,疼痛程度采用视觉模拟评分(VAS)评估,呕吐及发热的程度则根据CTCAE 4.0版评价。比较患者术前、术后3 d患者的肝功能。结果 DEB-TACE组患者的整体肿瘤客观反应率(ORR)高于cTACE组(58.8%比16.7%),差异有统计学意义(P=0.012)。DEB-TACE组患者的中位生存期为14(9, 24)个月,cTACE组为12(8, 24)个月,差异无统计学意义( P=0.697)。术后两组患者均未出现严重不良事件,但DEB-TACE组患者的栓塞后综合征发生率高于cTACE组(94.1% 比55.6%),差异有统计学意义(P=0.026),以腹痛为著(94.1%比44.4%),差异有统计学意义(P=0.002),两组患者术后均出现不同程度的肝功能损伤,差异无统计学意义(P>0.05)。结论 DEB-TACE治疗无远处转移的不可切除的ICC安全有效,短期疗效优于cTACE。

关键词: 载药微球, 肝内胆管细胞癌, 安全性, 有效性

Abstract: Objective To compare the efficacy and safety of transarterial chemoembolization using drug-eluting bead transarterial chemoembolization (DEB-TACE) and traditional transarterial chemoembolization (cTACE) in the treatment of unresectable intrahepatic cholangiocarcinoma (ICC).Methods From May 1, 2016 to May 1, 2021, thirty five patients with ICC in our hospital were retrospectively analyzed. Among them, 17 patients received DEB-TACE and 18 patients received cTACE. After 4 to 8 weeks, the patients were evaluated according to the solid tumor efficacy evaluation criteria (RECIST) and followed up for survival, and the efficacy of the treatments in two groups was compared. The postoperative adverse events were recorded and compared between the two treatment groups. The degree of pain was evaluated by visual analogue scale (VAS). The degree of vomiting and fever was evaluated according to CTCAE version 4.0 and the liver function of patients before and 3 days after operation was compared.Results The overall Objective response rate (ORR) of patients in the DEB-TACE group was significantly higher than that in the cTACE group (58.8% vs. 16.7%, P=0.012). The median survival period of patients in the DEB-TACE group was 14 (9, 24) months, which was longer that in the cTACE group 12 (8, 24) months (P=0.697). There were no severe adverse events in the two groups after operation, but the incidence of post-embolization syndrome in the DEB-TACE group was significantly higher than that in the cTACE group (94.1% vs. 55.6%, P=0.026), and abdominal pain was the most common symptom (94.1% vs. 44.4%, P=0.002). However, different degrees of liver function injury occurred in both groups after surgery, and the difference was not statistically significant (P>0.05).Conclusion DEB-TACE is safe and effective in the treatment of unresectable ICC without distant metastasis, and its short-term efficacy for unresectable ICC is better than that of cTACE.

Key words: Transarterial chemoembolization, Drug-eluting beads, Intrahepatic cholangiocarcinoma, Safety, Effective

何海涛, 刘尚大, 韦广旭, 许康祥, 周鹏程. 对比DEB-TACE与cTACE治疗不可切除的肝内胆管细胞癌的有效性及安全性[J]. 肝脏, 2022, 27(12): 1292-1295.

HE Hai-tao, LIU Shang-da, WEI Guang-xu, XU Kang-xiang, ZHOU Peng-cheng. The efficacy and safety of DEB-TACE compared with cTACE in the treatment of unresectable intrahepatic cholangiocarcinoma[J]. Chinese Hepatolgy, 2022, 27(12): 1292-1295.

参考文献

[1] Bray F, Ferlay J, Soerjomataram I,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018,68:394-424.
[2] Aliberti C, Benea G, Tilli M, et al. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol, 2008,31: 883-888.
[3] Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer, 2009,101:621-627.
[4] Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol, 2015, 16:967-978.
[5] Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol,2014,60:1268-1289.
[6] Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol,2012, 48:554-559.
[7] Kim JH, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer.2008,113: 1614-1622.
[8] 李婉慈, 朱晓黎, 王万胜, 等. 中晚期肝内胆管细胞癌介入治疗的临床疗效分析. 介入放射学杂志,2016, 25:813-817.
[9] Konstantinidis IT, Groot Koerkamp B, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer,2016, 122:758-765.
[10] 常中飞, 王茂强, 刘凤永, 等. 肝动脉化疗栓塞治疗肝内胆管细胞癌30例临床分析. 中华临床医师杂志(电子版),2013,7:2724-2726.
[11] Luo J, Zheng J, Shi C, et al. Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: a preliminary result from CTILC study. Medicine (Baltimore), 2020,99:e19276.
[12] Kuhlmann JB, Blum HE. Locoregional therapy for cholangiocarcinoma. Curr Opin Gastroenterol,2013,29: 324-328.
[13] Aliberti C, Carandina R, Lonardi S, et al. Transarterial chemoembolization with small drug-eluting beads in patients with hepatocellular carcinoma: experience from a cohort of 421 patients at an Italian Center. J Vasc Interv Radiol, 2017,28:1495-1502.

[1]	凌霞, 田尧. 熊去氧胆酸联合泼尼松龙规范化治疗原发性胆汁性胆管炎合并自身免疫性肝炎的疗效和安全性[J]. 肝脏, 2022, 27(7): 814-817.
[2]	瓦增成, 杜婷, 许惠晴, 乔志忠. 常规超声和超声造影对肝泡状棘球蚴病和肝内胆管细胞癌的鉴别诊断[J]. 肝脏, 2022, 27(5): 547-549.
[3]	李慧娟, 杨立品, 赵莎莎. 淋巴管、血管及神经侵犯对肝内胆管细胞癌术后复发和生存的影响[J]. 肝脏, 2022, 27(4): 466-469.
[4]	朱婷, 林立平, 韦玉亚. 超声造影成像特征及定量参数鉴别肝脏炎性假瘤与肝内胆管细胞癌的价值[J]. 肝脏, 2022, 27(3): 292-295.
[5]	阿卜来海提, 马森林, 陈明泉. CPS1及其LncRNA在胆管细胞癌诊治中的研究进展[J]. 肝脏, 2022, 27(3): 373-375.
[6]	甄勇, 王兵济, 杜华劲, 高学健, 王仔平, 宣佶, 张尊庶, 王传泰, 耿家宝. 抗凝治疗在肝硬化患者脾切除术后减少PVT的疗效及安全性研究[J]. 肝脏, 2022, 27(2): 169-173.
[7]	刘丽, 陈嘉兵, 陈成. 结肠癌肝转移应用聚乙烯醇载药微球介入栓塞的临床效果[J]. 肝脏, 2022, 27(2): 185-187.
[8]	肖崇娟, 张弢, 孙静, 范毓泽, 段学章, 何卫平. 射波刀治疗肝细胞癌腹腔淋巴结转移的疗效分析[J]. 肝脏, 2022, 27(10): 1069-1072.
[9]	刘念, 刘劲梧. ¹²⁵I粒子植入联合TIPS术治疗肝内胆管细胞癌门静脉主干癌栓合并门静脉高压的临床分析[J]. 肝脏, 2021, 26(10): 1115-1118.
[10]	房启楼, 倪建勋, 范红星, 金戈. TACE联合纳米粒治疗早期肝癌并发门静脉高压的疗效及安全性[J]. 肝脏, 2021, 26(1): 51-54.
[11]	段瑞芳, 杨道坤, 魏帅. TACE联合阿帕替尼治疗中晚期肝癌临床疗效与安全性的meta分析[J]. 肝脏, 2021, 26(1): 55-59.
[12]	陈晖, 左琳琳, 李木松, 刘猛. 肝细胞癌患者射频消融术治疗10年长期有效性分析[J]. 肝脏, 2020, 25(9): 922-925.
[13]	徐新宝, 殷杰, 吉浩明, 钱俐. S-TACE联合阿帕替尼对中晚期原发性肝癌患者肿瘤血管因子、肝功能和预后的影响[J]. 肝脏, 2020, 25(9): 933-936.
[14]	景仕银, 仲崇俊. 肝癌顽固性疼痛行左侧单孔胸腔镜[J]. 肝脏, 2020, 25(7): 769-771.
[15]	李银珍, 杜日昌, 丁宇, 徐彤, 廖罗飞. 肝内胆管细胞癌患者EGFR和Her-2表达水平评估预后的应用价值[J]. 肝脏, 2020, 25(6): 614-616.